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A B S T R A C T
Background
Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more
likely to develop recurrent venous thromboembolism (VTE).
Objectives
To compare the efficacy and safety of three types of parenteral anticoagulants for the initial treatment of VTE in patients with cancer.
Search methods
A comprehensive search for studies of anticoagulation in cancer patients including a February 2010 electronic search of: the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and ISI Web of Science.
Selection criteria
Randomized clinical trials (RCTs) comparing low molecular weight heparin (LMWH), unfractionated heparin (UFH), and fonda-
parinux in patients with cancer and objectively confirmed VTE.
Data collection and analysis
Using a standardized data form, data was extracted in duplicate on methodological quality, participants, interventions, and outcomes
of interest that included mortality, recurrent VTE, major bleeding, minor bleeding, postphlebitic syndrome, quality of life, and
thrombocytopenia.
Main results
Of 3986 identified citations, 16 RCTs were eligible: 13 compared LMWH to UFH, two compared fondaparinux to heparin, and one
compared dalteparin to tinzaparin. Meta-analysis of 11 studies showed a statistically significant reduction in mortality at three months
of follow up with LMWH compared with UFH (relative risk (RR) 0.71; 95% confidence interval (CI) 0.52 to 0.98). There was little
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change in the effect estimate after excluding studies of lower methodological quality (RR 0.72; 95% CI 0.52 to 1.00). A meta-analysis
of three studies comparing LMWH with UFH showed no statistically significant reduction in VTE recurrence (RR 0.78; 95% CI 0.29
to 2.08). The overall quality of evidence was low for LMWH versus UFH due to imprecision and likely publication bias. There were
no statistically significant differences between heparin and fondaparinux for the outcomes of death (RR 1.27; 95% CI 0.88 to 1.84),
recurrent VTE (RR 0.95; 95% CI 0.57 to 1.60), major bleeding (RR 0.79; 95% CI 0.39 to1.63) or minor bleeding (RR 1.50; 95%
CI 0.87 to 2.59). The one study comparing dalteparin to tinzaparin did not find a statistically significant difference in mortality (RR
0.86; 95% CI 0.43 to 1.73).
Authors’ conclusions
LMWH is possibly superior to UFH in the initial treatment of VTE in patients with cancer. Additional trials focusing on patient
important outcomes will further inform the questions addressed in this review.
P L A I N L A N G U A G E S U M M A R Y
Blood thinners for the initial treatment of blood clots in patients with cancer
Patients with cancer are at an increased risk of blood clots. The blood thinner administered in the first few days can consist of
unfractionated heparin (infused intravenously) or low molecular weight heparin (injected subcutaneously once or twice per day). These
two blood thinners may have different efficacies and safety profiles. In this systematic review, data from 13 studies suggest that low
molecular weight heparin is superior to unfractionated heparin in reducing mortality. However, there is not enough evidence to prove
superiority in reducing recurrence of blood clots. We did not find data to compare the safety profile of these two medications.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LMWH compared to UFH for the initial treatment of venous thromboembolism in patients with cancer
Patient or population: pat ients with the init ial t reatment of venous thromboembolism in pat ients with cancer
Settings: Inpat ient or outpat ient
Intervention: LMWH
Comparison: UFH
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
UFH LMWH
Death at 3 months
Follow-up: median 3
months
189 per 1000 134 per 1000
(98 to 185)
RR 0.71
(0.52 to 0.98)
801
(11 studies)
⊕⊕©©
low1,2,3
Recurrent VTE
Follow-up: median 3
months
96 per 1000 75 per 1000
(28 to 200)
RR 0.78
(0.29 to 2.08)
371
(3 studies)
⊕⊕©©
low3,4,5
Major bleeding - not re-
ported
See comment See comment Not est imable - See comment There is indirect evi-
dence that both LMWH
and UFH increase the
risk of major bleeding
compared with no ant i-
coagulat ion
Post phlebitic syn-
drome - not reported
See comment See comment Not est imable - See comment
Quality of life - not re-
ported
See comment See comment Not est imable - See comment
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Thrombocytopenia -
not reported
See comment See comment Not est imable - See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Of the 11 studies, 10 clearly concealed allocat ion, one blinded pat ients, providers or data collectors, 11 blinded outcome
adjudicators, and 10 used ITT.
2 A relat ively small number of events
3 We excluded 11 studies f rom the systematic review because the data for the cancer subgroup analysis was not reported. Of
the 13 included studies, only three reproted on the recurrence VTE outcome. An analysis of the same quest ion not restricted
to pat ients with cancer, demonstrated a likely publicat ion bias in favor of LMWH.
4 Of the 3 studies, 2 clearly concealed allocat ion, none blinded pat ients, providers or data collectors, 3 blinded outcome
adjudicators, and 2 used ITT.
5 CI includes values suggest ing benef it and values suggest ing harm
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B A C K G R O U N D
Glossary of terms found in Table 1
Description of the condition
Cancer status by itself increases the risk of venous thromboem-
bolism (VTE) by four to six fold (Heit 2000). In addition, ther-
apeutic interventions such as chemotherapy, hormonal therapy,
and indwelling central venous catheters increase the risk of VTE in
these patients (Heit 2000). Similarly, patients undergoing surgery
for cancer have a higher risk of VTE than those undergoing surgery
for benign diseases (Gallus 1997; Kakkar 1970). Patients with can-
cer and VTE have a higher risk of death than patients with cancer
alone or VTE alone (Levitan 1999; Sorensen 2002).
This heightened hypercoagulable state might alter the response to
anticoagulant treatment and the risk of bleeding. Compared to
patients without cancer, patients with cancer who receive antico-
agulant treatment for VTE are more likely to develop recurrent
VTE with an annual risk of 21% to 27%, a two to threefold risk
increase (Hutten 2000; Prandoni 2002). These patients are also
more likely to develop major bleeding with an annual risk of 12%
to 13%, a two to six fold risk increase (Hutten 2000; Prandoni
2002).
Description of the intervention
Heparin, low molecular weight heparins (LMWHs), fonda-
parinux, and danaparoid do not have intrinsic anticoagulant ac-
tivity but potentiate the activity of antithrombin III in inhibit-
ing activated coagulation factors. These agents constitute indirect
anticoagulants as their activity is mediated by plasma cofactors.
Recombinant hirudin, bivalirudin, and argatroban directly inhibit
thrombin and are classified as direct anticoagulants (Hirsh 2008).
Heparin and its low molecular weight derivatives are not absorbed
orally and must be administered parenterally by intravenous infu-
sion or subcutaneous injection (Hirsh 1993).
How the intervention might work
In the initial treatment of VTE, low molecular weight heparins
(LMWH) and unfractionated heparin (UFH) might have a differ-
ent comparative efficacy in patients with cancer than in patients
without cancer. Subgroup analyses of a Cochrane systematic re-
view showed that in patients without cancer there was no statis-
tically significant difference between the effects of LMWH and
UFH on overall mortality (odds ratio (OR) 0.97; 95% CI 0.61
to 1.56) (van Dongen 2007). However, in patients with cancer,
LMWH resulted in a lower overall mortality compared to UFH
(OR 0.53; 95% CI 0.33 to 0.85).
Why it is important to do this review
No systematic review has focused on the initial treatment of VTE
in patients with cancer. While the above mentioned Cochrane re-
view subgroup analysis compared the efficacy of these two drug
classes it did not report on the safety of LMWH and UFH in this
patient group. Furthermore, The Cochrane Collaboration has rec-
ognized that addressing all important outcomes including harm is
of great importance to make evidence-based health care decisions.
In addition, an analysis that includes an evaluation of direct com-
parative trials and subgroup analysis could prevent the potential
pitfalls of subgroup analysis (Oxman 2002). A subgroup refers to
a segment of the studied population with a specific characteristic
that is relevant to the question under consideration (for example
a subgroup of cancer patients with advanced disease).
O B J E C T I V E S
To compare the efficacy and safety of three types of parenteral
anticoagulants (that is fixed dose low molecular weight heparin,
adjusted dose unfractionated heparin, and fondaparinux) for the
initial treatment of VTE in patients with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Patients with cancer and a confirmed diagnosis of VTE (acute
deep venous thrombosis or pulmonary embolism). Patients could
have been of any age group (including pediatric patients) with
either solid or hematological cancer and at any stage of their cancer
irrespective of the type of cancer therapy.
To include patients, deep venous thrombosis should have been di-
agnosed using one the following objective diagnostic tests: venog-
raphy, 125I-fibrinogen uptake test, impedance plethysmography,
or Doppler ultrasound. Pulmonary embolism should have been
diagnosed using one the following objective diagnostic tests: pul-
monary perfusion or ventilation scans, computed tomography,
pulmonary angiography).
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Types of interventions
We considered comparisons of the following agents used in ini-
tial parenteral anticoagulation (typically the first five to 10 days):
LMWH, UFH, or fondaparinux. We excluded studies in which
thrombolytic therapy (for example streptokinase) was part of the
intervention. The protocol should have planned to provide all
other co-interventions (for example chemotherapy) similarly.
Types of outcome measures
Primary outcomes
• All cause mortality
Secondary outcomes
• Symptomatic recurrent deep venous thrombosis; events had
to be diagnosed using one of the following objective diagnostic
tests: venography, 125I-fibrinogen uptake test, impedance
plethysmography, or Doppler ultrasound
• Symptomatic recurrent pulmonary embolism; events had to
be diagnosed using one of the following objective diagnostic
tests: pulmonary perfusion or ventilation scans, computed
tomography, pulmonary angiography or autopsy
• Major bleeding
• Minor bleeding
• Postphlebitic syndrome
• Quality of life
• Thrombocytopenia
We accepted the authors’ definitions of major bleeding, minor
bleeding, thrombocytopenia, and postphlebitic syndrome as long
as they were standardized.
Search methods for identification of studies
Electronic searches
The search was part of a comprehensive search for studies of an-
ticoagulation in patients with cancer. We electronically searched
the following databases: Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2007, Issue 1), MED-
LINE (1966 onwards; accessed via Ovid), EMBASE (1980 on-
wards; accessed via Ovid), and ISI Web of Science (February
2010). The search strategies combined terms relating to the anti-
coagulants, cancer, and study design. We list the search strategies
in Appendix 1.
Searching other resources
We handsearched the conference proceedings of the American So-
ciety of Clinical Oncology (ASCO) (starting with its first volume,
1982) and American Society of Hematology (ASH) (starting with
its 2003 issue). We reviewed the reference lists of papers included
this review and of other relevant systematic reviews (Dolovich
2000; Gould 1999; Hettiarachchi 1999; Quinlan 2004; Siragusa
1996; van Dongen 2007). We used the related article feature in
PubMed to identify additional articles. We did not use language
restrictions.
Data collection and analysis
Selection of studies
Two authors independently screened the title and abstract of iden-
tified article citations for potential eligibility. We retrieved the full
text of articles judged potentially eligible by at least one author.
Two authors then independently screened the full text article for
eligibility using a standardized form with explicit inclusion and
exclusion criteria (as detailed in the ’Criteria for considering stud-
ies for this review’ section). The two authors resolved any disagree-
ments about which articles were eligible by discussion or by con-
sulting a third author.
Data extraction and management
We developed a data extraction form and pilot tested it. For En-
glish articles, two authors independently extracted the data from
each study and resolved their disagreements by discussion or by
consulting a third author. For non-English articles, one author
extracted data. The collected data related to the following.
Participants
• Demographic characteristics (e.g., age, sex)
• Cancer characteristics (e.g., type, location, stage, time since
diagnosis, estimated life expectancy, current cancer treatments,
performance status)
• Whether participants had deep venous thrombosis,
pulmonary embolism, or both
• Number of patients in each treatment arm
Interventions
• Type, dosage, and administration schedule of LMWH
• Dosage and administrative schedule of UFH
• Dosage schedule of fondaparinux
• Duration of initial parenteral therapy
• Type (oral anticoagulant versus LMWH) and duration of
long-term anticoagulation
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Outcomes
We attempted to extract both time to event data (for the survival
outcome) and categorical data (for all outcomes). However, none
of the studies reported time to event data for patients with can-
cer. For categorical data, we extracted the reported outcome data
necessary to conduct intention-to-treat analyses. Outcome event
rates were collected whenever they were reported in a trial. When
the authors did not report and could not provide the number of
events at specific time points, two biostatisticians estimated these
numbers independently and in duplicate from survival curves, if
available.
We attempted to contact authors for incompletely reported data.
We decided a priori to consider abstracts only if authors supplied
us with full reports of their methods and results.
Assessment of risk of bias in included studies
First, we assessed risk of bias at the study level using the Cochrane
risk of bias tool. Two review authors independently assessed the
methodological quality of each included study and resolved their
disagreements by discussion. Methodological criteria included the
following.
• Adequate sequence generation.
• Allocation concealment.
• Patient blinding.
• Provider blinding.
• Data collector blinding.
• Outcome assessor blinding.
• Analyst blinding.
• Percentage followed up and whether incomplete outcome
data were addressed.
• Whether the study was free of selective outcome reporting.
• Whether the study was stopped early for benefit.
• Whether the analysis followed the intention-to-treat (ITT)
principle.
Second, we assessed the quality of evidence at the outcome level us-
ing the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach (Cochrane Handbook).
Measures of treatment effect
We collected and analyzed risk ratios (RRs) for dichotomous data.
None of the outcomes of interest were meta-analyzed as a contin-
uous variable.
Unit of analysis issues
The unit of analysis was the individual participant.
Dealing with missing data
All but two included studies reported 100% follow up. We ana-
lyzed the available data assuming that any data that could be miss-
ing were missing at random.
Assessment of heterogeneity
Heterogeneity between trials was assessed by visual inspection of
forest plots, estimation of the percentage heterogeneity between
trials which cannot be ascribed to sampling variation (I2 statis-
tic) (Higgins 2003), and by a formal statistical test of the signif-
icance of the heterogeneity. If there was evidence of substantial
heterogeneity, the possible reasons for this were investigated and
reported.
Assessment of reporting biases
We assessed reporting bias by trying to identify whether the study
was included in a trial registry, whether a protocol was available,
and whether the methods section provided a list of outcomes (to
assess selective outcome reporting bias). We compared the list of
outcomes from those sources to the outcomes reported in the
published paper.
We assessed publication bias by creating an inverted funnel plot
for the primary outcome of survival. We used the trim and fill
technique to statistically evaluate the existence of publication bias (
Duval 2000).Wedidnot create funnel plots for the other outcomes
due to the low number of included trials for each outcome.
Data synthesis
We calculated the agreement between the two independent review
authors for the assessment of eligibility using the kappa statistic.
For dichotomous data, we calculated the RR separately for each
study. We then pooled the results of the different studies using a
random-effects model.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses based on characteristics of partici-
pants but did not conduct them as the needed data were not avail-
able.
Sensitivity analysis
We conducted sensitivity analysis by excluding studies with small
and unbalanced arms.
R E S U L T S
Description of studies
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Results of the search
The February 2010 search strategy identified a total of 8187 ci-
tations from which we removed the results of our January 2007
search. The title and abstract screening of the 8187 unique cita-
tions identified 59 as potentially eligible for this review. We in-
cluded 16 studies and excluded the remaining 43. Agreement be-
tween authors for study eligibility was excellent (kappa = 0.94).
Included studies
In all of the 16 included studies cancer patients constituted sub-
groups. Of these 16 studies, four studies reported data for the can-
cer subgroups (Prandoni 1992; Simmoneau 1993; Van Doormaal
2009 a; Van Doormaal 2009 b) and three studies (Breddin 2001;
Hull 1992; Merli 2001) had follow-up publications reporting the
cancer subgroup data (Green 1992; Kakkar 2000; Pineo 1997;
Rodgers 1999). For two studies, we obtained the cancer subgroup
data from the authors (Galilei 2004; Wells 2005). Seven studies
did not report cancer subgroup data (Columbus 1997; Duroux
1991; Koopman 1996; Levine 1996; Lindmaker 1994; Lopaciuk
1992; Simmoneau 1997) so we used the data as reported in two
published systematic reviews (Hettiarachchi 1999; van Dongen
2007).
Of the 16 studies, 13 compared a LMWH to UFH (total of 1016
participants), one compared dalteparin to tinzaparin (Wells 2005),
one compared fondaparinux to enoxaparin (Van Doormaal 2009
a), and one compared fondaparinux toUFH (VanDoormaal 2009
b). None of the studies specified the types of cancer of the partici-
pants. In 15 of the 16 studies the initial parenteral anticoagulation
was followed by oral anticoagulation for at least three months.
In Duroux 1991, the long-term anticoagulation was either UFH
subcutaneously or oral anticoagulation depending on the usual
regimen of the participating center (Duroux 1991).
Excluded studies
Of the 43 excluded studies, in 11 studies patients with cancer con-
stituted study subgroups but their outcome data were not available
(Albada 1989; Belcaro 1999; Bratt 1990; Buller 2004; Fiessinger
1996; Harenberg 1990;Harenberg 2000;Holm 1986;Hull 2000;
Luomanmaki 1996; Riess 2003). We excluded the remaining 32
studies for the following reasons: review (11), case report or series
(4), letter to the editor or editorial (4), cohort study (3), no pa-
tients with cancer included (3), retrospective study (2), no relevant
outcome (2), different long-term management (1), not random-
ized (1), survey (1).
Risk of bias in included studies
Allocation
Allocation was adequately concealed in 14 studies; it was not clear
whether it was adequately concealed in two studies (Breddin 2001;
Duroux 1991).
Blinding
All studies blinded outcome assessors. Only two studies blinded
data analysts (Galilei 2004; Wells 2005) and only three studies
blinded patients and caregivers (Hull 1992; Van Doormaal 2009
a; Wells 2005).
Incomplete outcome data
Follow up was 89% for Breddin 2001, 92% for Duroux 1991,
and 100% for the remaining studies.
Selective reporting
We did not suspect selective reporting of outcomes for any of the
studies. The cancer subgroup data weremissing for a large number
of studies.
Other potential sources of bias
Thirteen studies clearly used intention-to-treat analysis (Duroux
1991; Galilei 2004; Hull 1992; Koopman 1996; Levine 1996;
Lindmaker 1994; Lopaciuk 1992; Merli 2001; Prandoni 1992;
Simmoneau 1997; Van Doormaal 2009 a; Van Doormaal 2009 b;
Wells 2005). None of the studies were stopped early for benefit.
Effects of interventions
See: Summary of findings for the main comparison LMWH
compared to UFH for the initial treatment of venous
thromboembolism in patients with cancer; Summary of findings
2 Fondaparinux compared to heparin for the initial treatment of
venous thromboembolism in patients with cancer
Low molecular weight heparin versus unfractionated
heparin
Mortality
The number of fatal events was available for 11 studies (801
patients) at three months follow up (Columbus 1997; Duroux
1991; Galilei 2004; Hull 1992; Koopman 1996; Levine 1996;
Lindmaker 1994; Lopaciuk 1992; Prandoni 1992; Simmoneau
1993; Simmoneau 1997). The pooled analysis showed a statis-
tically significant mortality reduction in patients treated with
LMWH compared with those treated with UFH (RR 0.71; 95%
CI 0.52 to 0.98) (Figure 1). No heterogeneity was present (I2 =
0%). After excluding the three studies with small and imbalanced
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arms (Duroux 1991; Lopaciuk 1992; Simmoneau 1993) the ben-
efit remained borderline statistically significant (RR 0.72; 95%CI
0.52 to 1.00). The figure shows the inverted funnel plot for the
outcome of death (Figure 2). The trim and fill technique did not
suggest publication bias but we still suspected it because 11 studies
did not report cancer subgroup data. Figure 3 summarizes the risk
of bias for studies assessing this outcome. The quality of the body
of evidence for mortality was low due to imprecision and likely
publication bias (Summary of findings for the main comparison).
Figure 1. Forest plot of comparison: 1 LMWH vs. UFH, outcome: 1.1 Death at 3 months.
9Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Inverted funnel plot for studies comparing the effect on mortality of LMWH and UFH as the
initial anticoagulation in cancer patients with venous thromboembolism
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for included
studies assessing mortality (LMWH vs. UFH).
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Recurrent venous thromboembolism (VTE)
No data were available for deep venous thrombosis or pulmonary
embolism events separately. The data for recurrent VTE events
were available for three studies (Breddin 2001; Galilei 2004;Merli
2001). The pooled analysis showed a non-statistically significant
advantage of LMWH over UFH (RR 0.78; 95% CI 0.29 to 2.08)
with low heterogeneity (I2 = 32.4%) (Figure 4). Figure 5 sum-
marizes the risk of bias for studies assessing this outcome. The
quality of the body of evidence for recurrent VTE was low due to
imprecision and likely publication bias (Summary of findings for
the main comparison).
Figure 4. Forest plot of comparison: 1 LMWH vs. UFH, outcome: 1.2 Recurrent VTE.
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Figure 5. Risk of bias summary: review authors’ judgements about each risk of bias item for included
studies assessing recurrent VTE (LMWH vs. UFH).
No data were available for bleeding outcomes, thrombocytopenia,
postphlebitic syndrome, or quality of life.
Fondaparinux versus unfractionated heparin (UFH)
The pooled results of the two studies comparing fondaparinux to
heparin (Van Doormaal 2009 a; Van Doormaal 2009 b) showed
no statistically significant difference between the two agents for
the outcomes of death (RR 1.27; 95% CI 0.88 to 1.84), recur-
rent VTE (RR 0.95; 95% CI 0.57 to 1.60), major bleeding (RR
0.79; 95% CI 0.39 to1.63), or minor bleeding (RR 1.50; 95%
CI 0.87 to 2.59). Figure 6 summarizes the risk of bias for these
two studies. The quality of the body of evidence was moderate for
mortality,major bleeding, andminor bleeding due to imprecision;
and low for recurrent VTE due to inconsistency and imprecision
(Summary of findings 2).
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Figure 6. Risk of bias summary: review authors’ judgements about each risk of bias item for included
studies (fondaparinux vs. heparin).
No data were available for thrombocytopenia, postphlebitic syn-
drome, or quality of life.
Dalteparin versus tinzaparin
The study comparing dalteparin to tinzaparin (Wells 2005) found
no statistically significant difference for the outcomes of death (RR
0.86; 95% CI 0.43 to 1.73), VTE recurrence (RR 0.44; 95% CI
0.09 to 2.16), major bleed (RR 2.19; 95% CI 0.20 to 23.42), or
minor bleed (RR0.82; 95%CI 0.30 to 2.21). Figure 7 summarizes
the risk of bias for this study. The overall quality of evidence was
moderate, due to imprecision.
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Figure 7. Risk of bias summary: review authors’ judgements about each risk of bias item for the included
study (dalteparin to tinzaparin).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Fondaparinux compared to heparin for the initial treatment of venous thromboembolism in patients with cancer
Patient or population: pat ients with the init ial t reatment of venous thromboembolism in pat ients with cancer
Settings: Inpat ient or outpat ient
Intervention: Fondaparinux
Comparison: heparin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
heparin Fondaparinux
Death
Follow-up: median 3
months
Study population RR 1.27
(0.88 to 1.84)
477
(2 studies)
⊕⊕⊕©
moderate1,2
172 per 1000 218 per 1000
(151 to 316)
Medium risk population
170 per 1000 216 per 1000
(150 to 313)
Recurrent VTE
Follow-up: median 3
months
Study population RR 0.95
(0.57 to 1.6)
477
(2 studies)
⊕⊕©©
low1,2,3
117 per 1000 111 per 1000
(67 to 187)
Medium risk population
113 per 1000 107 per 1000
(64 to 181)
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Major bleeding
Follow-up: median 3
months
Study population RR 0.79
(0.39 to 1.63)
477
(2 studies)
⊕⊕⊕©
moderate1,3
There is indirect evi-
dence that both fonda-
parinux and heparin in-
crease the risk of bleed-
ing compared with no
ant icoagulat ion
67 per 1000 53 per 1000
(26 to 109)
Medium risk population
67 per 1000 53 per 1000
(26 to 109)
Minor bleeding
Follow-up: median 3
months
Study population RR 1.5
(0.87 to 2.59)
477
(2 studies)
⊕⊕⊕©
moderate2,4
There is indirect evi-
dence that both fonda-
parinux and heparin in-
crease the risk of bleed-
ing compared with no
ant icoagulat ion
79 per 1000 119 per 1000
(69 to 205)
Medium risk population
81 per 1000 122 per 1000
(70 to 210)
Post phlebitic syn-
drome - not reported
See comment See comment Not est imable - See comment
Quality of life - not re-
ported
See comment See comment Not est imable - See comment
Thrombocytopenia -
not reported
See comment See comment Not est imable - See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Of the 2 studies, both concealed allocat ion, one blinded pat ients, providers, data collectors and outcome adjudicators, both
used ITT and none was stopped early for benef it
2 CI includes values suggest ing benef it and values suggest ing harm
3 I2=85%
4 I2=38%
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D I S C U S S I O N
Summary of main results
This systematic review found a patient important and statistically
significant mortality reduction with the use of LMWH compared
to UFH in the initial treatment of VTE in patients with cancer.
The comparative effect on the incidence of VTE was not statisti-
cally significant. There were no statistically significant differences
between fondaparinux and heparin nor between dalteparin and
tinzaparin in the effects on the outcomes of interest.
Overall completeness and applicability of
evidence
The completeness of the data is a major concern in this systematic
review. First, of a total of 24 potentially eligible studies we did
not include 11 because the authors did not report the needed
subgroup data for patients with cancer. These 11 studies would
have contributed 340 additional participants to the meta-analysis
(801 are currently included). If the treatment effect from those
studies was different from the reported effect, their exclusion from
the meta-analysis could have biased our results. Moreover, only
three of the included studies reported cancer subgroup data for
VTE recurrence and none reported cancer subgroup data for the
bleeding outcomes.
Second, there is evidence of publication bias in favor of LMWH
even when considering all studies comparing subcutaneous UFH
to LMWH in the initial management of VTE for any patient
(with or without cancer) (see Figure 8, Figure 9, Figure 10 from an
unpublished analysis). This affects our confidence in the results of
the current analysis suggesting superiority of LMWH over UFH.
Figure 8. Funnel plot for mortality outcome for LMWH vs. SC UFH in all patients (unpublished)
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Figure 9. Funnel plot for recurrent VTE outcome for LMWH vs. SC UFH in all patients (unpublished)
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Figure 10. Funnel plot for major bleeding outcome for LMWH vs. SC UFH in all patients (unpublished)
Quality of the evidence
For the LMWH versus UFH comparison, the methodological
quality for death and recurrent VTE outcomes was low due to im-
precision and likely publication bias. For the fonaparinux versus
heparin comparison, the quality of evidence was low for recurrent
VTE (due to imprecision and inconsistency) and moderate for
mortality and bleeding outcomes (due to imprecision). For the
dalteparin versus tinzaparin comparison, the quality of evidence
was also moderate for the outcomes of interest due to imprecision.
Potential biases in the review process
A potential limitation of our review is the limitation of the elec-
tronic search strategy to patientswith cancer, while the data needed
for this review came from studies not restricted to this subgroup.
However, we think that the supplemental search strategies we used
(in addition to the electronic search) were effective. In fact, our
search strategy did not miss any of the studies reported in earlier
systematic reviews on the topic.
Agreements and disagreements with other
studies or reviews
Three previous systematic reviews compared the effects of LMWH
and UFH on mortality in patients with cancer and with VTE.
A 1999 review by Hettiarachchi et al included nine studies and
629 patients and resulted in an OR of 0.61 (95% CI 0.40 to
0.93) (Hettiarachchi 1999). A review by Gould et al included
279 patients and resulted in an OR of 0.57 (95% CI 0.31 to
1.03) (Gould 1999). Van Dongen et al conducted, in a Cochrane
review, a subgroup analysis for patients with cancer and included
six studies and446patients; it showed anORof 0.53 (95%CI0.33
to 0.85) (van Dongen 2007). While the current review includes
more studies and patients (11 studies and 801 patients) than the
three previous reviews, the resulting effect is consistent.
The two reviews by Hettiarachchi et al and van Dongen et al
assessed the comparative efficacy of LMWH and UFH separately
in patients with and without cancer (Hettiarachchi 1999; van
Dongen 2007). While LMWH was superior to UFH in patients
with cancer, as noted above, they were statistically equivalent in
patients without cancer, with respectiveORs of 0.94 (95%CI 0.60
to 1.47) and 0.97 (95% CI 0.61 to 1.56). However, the authors
did not report testing statistically for subgroup effect.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
LMWH is possibly superior to UFH in reducing mortality in the
initial treatment of VTE in patients with cancer. The confidence
in this effect is reduced by both the risk of bias in included studies
and the likelihood of publication bias. However, there are addi-
tional advantages of LMWH related to subcutaneous administra-
tion and outpatient management (O’Brien 1999; Othieno 2007).
One factor a patient might need to take into account when mak-
ing this choice is the potential increase in out of pocket expenses
with LMWH.
Implications for research
There is a need to conduct trials comparing anticoagulants in the
initial treatment of VTE that are restricted to patients with cancer.
Researchers should considermaking the rawdata ofRCTs available
for individual patient data meta-analysis. Also, as recognized by
the Cochrane Collaboration, addressing all important outcomes
including harm is of great importance in making evidence-based
healthcare decisions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Breddin 2001
Methods Randomized controlled open label trial
Participants 74 cancer patients with DVT but not PE (study subgroup); minimum age of 18 years
Interventions Intervention: reviparin weight based subcutaneous twice daily
Control: UFH IV (continuous infusion of 1250 IU/hour) x 5-7 days
Vitamin K antagonist (target INR >2) started on day 1 x 90 days
A third group received reviparin subcutaneous once day x 28 days and vitamin K antag-
onist on days 21-90
Outcomes Mortality, symptomatic DVT (not clear whether asymptomatic events included), PE,
major bleeding
Notes Funding: Knoll, Germany
Follow up: 90 days
Radiological surveillance: venography surveillance for DVT conducted at day 21
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned to
one of three groups, stratified according to
site.”
Comment: definitely yes
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of patients? High risk Quote: “open-label trial”
Comment: probably no
Blinding of providers? High risk Quote: “open-label trial”
Comment: probably no
Blinding of data collectors? High risk Quote: “open-label trial”
Comment: probably no
Blinding of outcome adjudicators? Low risk Quote: “The venogram were assessed by two
members of an independent committee who
were unaware of the patients’ treatment as-
signments and of whether the venogramswere
obtained before or after treatment.”
Comment: definitely yes
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Breddin 2001 (Continued)
Blinding of data analysts? Unclear risk Not reported
Comment: probably no
Incomplete outcome data addressed? Low risk 89% follow-up rate for VTE recurrence
Intention to treat analysis? Unclear risk Not reported
Free of selective reporting? Low risk Study not registered. No published protocol.
All outcomes listed in the methods section
reported on
Free of other bias? Low risk Study not stopped early for benefit
Columbus 1997
Methods Randomized controlled trial
Participants 232 cancer patients with proximal or distal DVT, PE or both; minimum age of 18 years
Interventions Intervention: reviparin weight based subcutaneous twice daily at home
Control: UFH IV (target aPTT 1.5-2.5) in the hospital x 5 days. Coumarin derivative
(target INR >2) started on 1st or 2nd day x 12 weeks
Outcomes Mortality, recurrent symptomatic venous thromboembolism, bleeding
Notes Funding: Knoll AG
Follow up: 12 weeks
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: patients could be treated at home, but he decision to do so was left to the treating
physician
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performedwith a computer
algorithm.”
Comment: definitely yes
Allocation concealment (selection bias) Low risk Quote: “Randomization was performedwith a computer
algorithm and the use of a central 24-hour telephone
service that recorded information on the patient before
the treatment assignment was disclosed.”
Comment: central randomization
Blinding of patients? High risk Quote: “open international, randomized clinical trial”
Comment: probably not
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Columbus 1997 (Continued)
Blinding of providers? High risk Quote: “open international, randomized clinical trial”
Comment: probably not
Blinding of data collectors? High risk Quote: “open international, randomized clinical trial”
Comment: probably not
Blinding of outcome adjudicators? Low risk Quote: “Information on all suspected outcome events
and deaths was reviewed and classified by a central ad-
judication committee whose members were unaware of
the treatment assignments.”
Comment: definitely yes
Blinding of data analysts? Unclear risk unclear
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Unclear risk Not reported
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant
outcomes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Duroux 1991
Methods Randomized controlled trial
Participants 18 cancer patients with proximal DVT but no PE; minimum age 18 years
Interventions Intervention: CY216 (fraxiparin) 255 antiXa U/Kg twice daily x 10 days
Control: UFH IV (target aPTT 1.5-2) x10 days
After day 10 each center continued its usual anticoagulant regimen either by subcuta-
neous UFH at adjusted doses or by oral anticoagulants x 12 weeks
Outcomes Death, venous thromboembolism (venogram detected DVT), bleeding
Notes Funding: Sanofi-Choay
Follow up: 12 weeks
Radiological surveillance:venography surveillance for DVT conducted at day 10
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Study was a randomized parallel group trial”
Comment: probably yes
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Duroux 1991 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of patients? High risk Quote: “Treatment could not be given double-blinded
because of the different methods of administration and
primarily the need for dose adjustment in the UFH
group.”
Comment: probably not
Blinding of providers? High risk Quote: “Treatment could not be given double-blinded
because of the different methods of administration and
primarily the need for dose adjustment in the UFH
group.”
Comment: probably not
Blinding of data collectors? High risk Quote: “Treatment could not be given double-blinded
because of the different methods of administration and
primarily the need for dose adjustment in the UFH
group.”
Comment: probably not
Blinding of outcome adjudicators? Low risk Quote: “Principal judgement criterion was evaluated
blinded by two independent radiologists(coded films).”
Comment: definitely yes
Blinding of data analysts? High risk Quote: “Treatment could not be given double-blinded
because of the different methods of administration and
primarily the need for dose adjustment in the UFH
group.”
Comment: probably not
Incomplete outcome data addressed? Low risk 92% follow-up rate.
Intention to treat analysis? Low risk Quote: “An intention-to-treat analysis including patients
with premature cessation of treatment but in whom there
was a D10 venogram was also undertaken.”
Comment: probably yes
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant
outcomes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
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Galilei 2004
Methods Randomized controlled study
Participants 156 cancer patients (study subgroup) with DVT of lower extremities and/or PE; mini-
mum age of 18 years; minimum life expectancy of 3 months
Interventions Intervention: nadroparin 80U/kg twice daily
Control: UFH 1st dose weight adjusted IV, subsequent doses SC twice daily (target
aPTT 50-90s) x 5 days warfarin (target INR 2-3) started the first two days x 12 weeks
Outcomes Death; symptomatic recurrent VTE ; major bleeding, heparin induced thrombocytope-
nia
Notes Funding: Gentium SpA, Como, Italy
Follow up: 3months
Radigological surveillance: no scheduled radiological surveillance forVTEwas conducted
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed with a com-
puter algorithm.”
Comment: definitely yes
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed with a com-
puter algorithm and the use of a 24 hour telephone ser-
vice that recorded patient information before disclosure
of the treatment assigned.”
Comment: definitely yes
Blinding of patients? High risk Quote: “open multicenter clinical trial”
Comment: probably not
Blinding of providers? High risk Quote: “open multicenter clinical trial”
Comment: probably not
Blinding of data collectors? High risk Quote: “open multicenter clinical trial”
Comment: probably not
Blinding of outcome adjudicators? Low risk Quote: “Information on all suspected outcome events
and deaths was reviewed and classified by a central adju-
dication committee blinded to treatment assignment”
Comment: definitely yes
Blinding of data analysts? Low risk Quote: “open multicenter clinical trial”
Comment: probably not
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Galilei 2004 (Continued)
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk Quote: “Both analyses were performed on an intention-
to-treat basis and included all patients who were ran-
domly assigned to either strategy”
Comment: definitely yes
Free of selective reporting? Low risk Study not registered. No published protocol. All rele-
vant outcomes listed in the methods section were re-
ported on
Free of other bias? Low risk Study not stopped early for benefit
Hull 1992
Methods Randomized controlled trial
Participants 95 cancer patients with proximal DVT (study subgroup); minimum age of 18 years
Interventions Intervention: tinzaparin 175 antiXa U/kg subcutaneous once daily
Control: UFH IV (target aPTT 1.5-2.5) x 6 days
Warfarin (target INR 2-3) started on day 2 for 3 months
Outcomes Mortality, symptomatic venous thromboembolism, bleeding
Notes Funding: Heart and Stroke Foundation of Alberta and Novo Nordisk
Follow up: 3 months
Radiologica surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: inpatient
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A randomized, computer-derived treatment
schedule was used to assign the patients to receive intra-
venous heparin or subcutaneous low molecular-weight
heparin.”
Allocation concealment (selection bias) Low risk Quote: “Before randomization, patients were stratified
into groups according to a randomized, computer-de-
rived treatment schedulewas used to assign the patients to
receive intravenous heparin or subcutaneous low molec-
ular-weight heparin.”
Comment: probably yes
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Hull 1992 (Continued)
Blinding of patients? Low risk Quote: “double blinded clinical trial.”
Comment: probably yes
Blinding of providers? Low risk Quote: “double blinded clinical trial.”
Comment: probably yes
Blinding of data collectors? Low risk Quote: “double blinded clinical trial.”
Comment: probably yes
Blinding of outcome adjudicators? Low risk Quote: “Central adjudication committee was made by
two committee members not involved in the patient’s
care, and disputes were resolved independently by a third.
”
Comment: definitely yes
Blinding of data analysts? High risk Quote: “double blinded clinical trial.”
Comment: probably not
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk No loss to followup and all patients randomized included
in the analyses of outcomes
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Koopman 1996
Methods Randomized controlled study
Participants 70 cancer patients with proximal DVT without PE (study subgroup); minimum age of
18 years; minimum life expectancy of 6 months
Interventions Intervention: nadroparin weight based subcutaneous twice daily at home
Control: UFH IV (target aPTT 1.5-2) x 5 days
Oral anticoagulation (target INR 2-3) started x 3 months
Outcomes Death, recurrent symptomatic venous thromboembolism, major bleeding
Notes Funding: Sanofi Winthrop
Follow up: 6 months
No scheduled radiological surveillance for VTE was conducted
Setting: standard heparin was administered at the hospital and LMWH patient were
allowed to be treated at home
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Koopman 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After the patients gave informed consent, ran-
domization (stratified according to center) was achieved
by means of a central 24 hour telephone service.”
Allocation concealment (selection bias) Low risk Quote: “After the patients gave informed consent, ran-
domization (stratified according to center) was achieved
by means of a central 24 hour telephone service.”
Blinding of patients? High risk Quote: “This was an unblinded study”
Blinding of providers? High risk Quote: “This was an unblinded study”
Blinding of data collectors? High risk Quote: “This was an unblinded study”
Blinding of outcome adjudicators? Low risk Quote: “Documentation of all potential outcome
events, including deaths, was submitted to an indepen-
dent adjudication committee whose members were un-
aware of the treatment assignments.”
Blinding of data analysts? High risk Quote: “This was an unblinded study”
Incomplete outcome data addressed? Low risk 99% follow-up rate
Intention to treat analysis? Low risk Quote: “The analyses were performed on an intention
to treat basis”
Free of selective reporting? Low risk Study not registered. No published protocol. All the
outcomes listed in the methods section were reported
on
Free of other bias? Low risk Study not stopped early for benefit
Levine 1996
Methods Randomized controlled study
Participants 103 cancer patients with proximal or distal DVT without PE (study subgroup)
Interventions Intervention: enoxaparin 1 mg/kg subcutaneous twice daily at home
Control: UFH IV (target aPTT 60-85s) x 5 days
Warfarin (target INR 2-3) started on evening of 2nd day for at least 3 months
Outcomes Death, recurrent symptomatic venous thromboembolism, bleeding
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Levine 1996 (Continued)
Notes Funding: not reported
Follow up: 90 days
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: LMWH given as outpatient (mean hospital stay=1.1±2.9 days); UFH given as
inpatient (mean hospital stay=2.2±3.8 days)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned to treatment through
randomization over the telephone from a central line”
Comment: definitely yes
Allocation concealment (selection bias) Low risk Quote: “Patients were assigned to treatment through
randomization over the telephone from a central line”
Comment: definitely yes
Blinding of patients? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of providers? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of data collectors? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of outcome adjudicators? Low risk Quote: “All reported outcome events were reviewed by
a central adjudication committee whose members were
unaware of the treatment assignments”
Comment: definitely yes
Blinding of data analysts? High risk Comment: probably not as no mention of blinding
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk No clear mention of ITT analysis. However, probably
yes as no patients were lost to follow up and there was
no mention of cross over
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
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Lindmaker 1994
Methods Randomized controlled study
Participants 16 cancer patients with DVT (below the inguinal ligament) but no PE (study subgroup)
; minimum age of 18 years
Interventions Intervention: Fragmin 200 IU/Kg subcutaneous once daily
Control: UFH IV (target aPTT 1.5-3) x 5 days
Warfarin (target INR 2-3) x 3 months
Outcomes Death, symptomatic pulmonary embolism, bleeding
Notes Funding: Pharmacia AB
Follow up: 6 months
Radiological surveillance:no scheduled radiological surveillance for VTE was conducted
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was organized centrally using
sealed envelopes stratified for each center in a block size
of 20”
Allocation concealment (selection bias) Low risk Quote: “Randomization was organized centrally using
sealed envelopes stratified for each center in a block size
of 20”
Blinding of patients? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of providers? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of data collectors? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of outcome adjudicators? Low risk Quote: “All venogramswere interpreted by a radiologist
who did not know which of the treatments the patient
had received or in which order the venogram has been
performed.”
Blinding of data analysts? High risk Comment: probably not as no mention of blinding
Incomplete outcome data addressed? Low risk 100% follow-up rate
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Lindmaker 1994 (Continued)
Intention to treat analysis? High risk “Of the 204 patients, 14 treated with UFH and 10 with
Fragmin were excluded from the efficacy analysis”
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Lopaciuk 1992
Methods Randomized controlled trial
Participants 9 cancer patients with proximal or calf DVT without PE (study subgroup)
Interventions Intervention: nadroparin 92 antiXa U/kg twice daily
Control: UFH 1st dose IV, subsequent dose subcutaneous twice daily (target aPTT 1.
5-2.5) x 10 days
Acenocoumarol (target INR 2-3) started the 7th day x at least 3 months
Outcomes Death, symptomatic pulmonary embolism, recurrent DVT, bleeding
Notes Funding: Sanofi
Follow up: 3 months
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Study was a prospective, open, stratified, and
randomized multicenter trial with a blind evaluation of
phlebographic results”
Allocation concealment (selection bias) Low risk Quote: “they were randomly allocated by using a sealed
envelope to either Fraxiparine or UFH group”
Comment: no mention of sequential numbering and
opacity
Blinding of patients? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
Blinding of providers? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
Blinding of data collectors? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
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Lopaciuk 1992 (Continued)
Blinding of outcome adjudicators? Low risk Quote: “blind evaluation of phlebographic results”
Comment: yes for evaluation of DVT events
Blinding of data analysts? High risk Comment: probably not as no mention of blinding
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk No clear mention of ITT analysis. However, probably
yes as no patients were lost to follow up and there was
no mention of cross over
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk study not stopped early for benefit
Merli 2001
Methods Randomized controlled trial
Participants 141 cancer patients with DVT or PE (study subgroup); minimum age of 18 years
Interventions Intervention: enoxaparin 1 mg/kg subcutaneous twice daily or 1.5 mg/kg subcutaneous
once daily Control: UFH IV (target aPTT 55-80s) x 5 days
Warfarin (target INR 2-3) started within 72h x 3 months
Outcomes Mortality, symptomatic recurrent VTE, bleeding, drug induced thrombocytopenia
Notes Funding: Aventis
Follow up: 3 months
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned”
Allocation concealment (selection bias) Low risk Quote: “Randomization numbers were affixed to sealed
treatment kits that contained study medication and were
provided by the study sponsor”
Blinding of patients? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
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Merli 2001 (Continued)
Blinding of providers? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
Blinding of data collectors? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
Blinding of outcome adjudicators? Low risk Quote: “Outcome adjudication committee, which pro-
vided blinded outcome assignments for incidence out-
comes”
Blinding of data analysts? High risk Comment: probably not as no mention of blinding and
the compared drugs administered using 2 different routes
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk Quote: “The efficacy analysis was performed on two
study samples: all treated patients, who received at least
one dose of study medication, and evaluable patients,
which excluded all patients who met at least one of the
criteria for non evaluability”
Comment: the first analysis is ITT
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Prandoni 1992
Methods Randomized controlled trial
Participants 33 cancer patients with proximal DVT (study subgroup), minimum age of 18 years
Interventions Intervention: enoxaparin weight based subcutaneous twice daily
Control: UFH IV (target aPTT 1.5-2.0) x 10 days
Coumarin (target INR 2-3) started on day 7 for at least 3 months
Outcomes Death, symptomatic recurrent DVT, symptomatic pulmonary embolism
Notes Funding: not reported
Follow up: 1, 3, 6 months
Radiological surveillance:no scheduled radiological surveillance for VTE was conducted
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Prandoni 1992 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated treatment by a prescribed
randomisation schedule.”
Comment: definitely yes
Allocation concealment (selection bias) Low risk Quote: “Treatment was allocated by the sealed envelop
method”
Comment: definitely yes
Blinding of patients? High risk Quote: “Because the two regimenswere givenby different
routes and because dose adjustments were necessary in
the standard heparin group, we could not use a double
blind design”
Comment: probably not
Blinding of providers? High risk Quote: “Because the two regimenswere givenby different
routes and because dose adjustments were necessary in
the standard heparin group, we could not use a double
blind design”
Comment: probably not
Blinding of data collectors? High risk Quote: “Because the two regimenswere givenby different
routes and because dose adjustments were necessary in
the standard heparin group, we could not use a double
blind design”
Comment: probably not
Blinding of outcome adjudicators? Low risk Quote: “All clinical endpoints were reviewed by an ad-
judication committee from the coordinating center, un-
aware of treatment allocation or other details of patients.
”
Comment: definitely yes
Blinding of data analysts? High risk Quote: “Because the two regimenswere givenby different
routes and because dose adjustments were necessary in
the standard heparin group, we could not use a double
blind design”
Comment: probably not
Incomplete outcome data addressed? Low risk 100% follow-up rate.
Intention to treat analysis? Low risk Quote: “intention to treat analysis was used”
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
40Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Simmoneau 1993
Methods Randomized controlled study
Participants 9 cancer patients with proximal DVT (study subgroup); minimum age of 18 years
Interventions Intervention: enoxaparin 1 mg/kg subcutaneous twice daily
Control: UFH IV (target aPTT 1.5-2.5) x 10 days
Oral anticoagulation (target INR 2-3) started on day 10 for at least 3 months
Outcomes Death, recurrent symptomatic venous thromboembolism, bleeding
Notes Funding: not reported
Followup: 3 months
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization code was drafted bymeans
of a standard random number table randomizing in
blocks of four”
Allocation concealment (selection bias) Low risk Quote: “The patients’ treatment assignments were
taken from sealed envelopes.”
Blinding of patients? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of providers? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of data collectors? High risk Comment: probably not as no mention of blinding
and the compared drugs administered using 2 different
routes
Blinding of outcome adjudicators? Low risk Quote: “Venograms, perfusion lung scans, and pul-
monary angiograms were subsequently reviewed by a
central independent panel of two consultant specialists
unaware of the treatment allocation”
Comment: definitely yes
Blinding of data analysts? High risk Comment: probably not as no mention of blinding
Incomplete outcome data addressed? Low risk 100% follow-up rate
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Simmoneau 1993 (Continued)
Intention to treat analysis? Low risk No clear mention of ITT analysis. However, probably
yes as no patients were lost to follow up and there was
no mention of cross over
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Simmoneau 1997
Methods Randomized controlled trial
Participants 60 cancer patients with PE (study subgroup); minimum age of 18 years; minimum life
expectancy of 3 months
Interventions Intervention: tinzaparin 175 antiXa U/kg subcutaneous once daily
Controll: UFH IV (target aPTT 2-3) x 5 days
Oral anticoagulation (target INR 2-3) started on 1st to 3rd day x at least 3 months
Outcomes Death, symptomatic recurrent venous thrombus, major bleeding
Notes Funding: Leo Pharmaceuticals
Follow up: 90 days
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: the mean duration of anticoagulant treatment at a therapeutic dose before ran-
domization was 18+/-6 hours in the patients assigned to unfractionated heparin and
18+/- 7hours in the patients assigned to low molecular weight heparin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “central randomization was performed”
Allocation concealment (selection bias) Low risk Quote: “central randomization was performed with the
use of a 24 hour computer service”
Blinding of patients? High risk Quote: “unblinded trial”
Comment: probably not
Blinding of providers? High risk Quote: “unblinded trial”
Comment: probably not
Blinding of data collectors? High risk Quote: “unblinded trial”
Comment: probably not
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Simmoneau 1997 (Continued)
Blinding of outcome adjudicators? Low risk Quote: “All the scans were reviewed independently and
scored accordingly to this method by two readers, each
unaware of the patient’s treatment assignment”
Comment: definitely yes
Blinding of data analysts? High risk Quote: “unblinded trial”
Comment: probably not
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk Quote: “The primary analysis was performed on an in-
tention to treat basis”
Comment: definitely yes
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Van Doormaal 2009 a
Methods Randomized controlled study
Participants 237 cancer patients with DVT, minimum age 18 years
Interventions Intervention: fondaparinx was given subcutaneously once daily in fixed dose (5 mg if
patients weighted less than 50 kg, or 7.5 mg if they weighted between 50 and 100 kg,
or 10 mg if they weighted more than 100kg) and also received twice daily subcutaneous
injections of placebo that appeared identical to enoxaparin
Control: enoxaparin was given subcutaneously twice daily in a dose of 1mg/kg of body
weight and a once daily subcutaneous injections of placebo that appeared identical to
fondaparinux
In all patients, VKA therapy was begun as soon as possible but not later than 72 hours
after commencing initial therapy
Outcomes Death, symptomatic recurrent VTE, bleeding
Notes Funding: Sanofi/ Organon
Follow up: 90 days
Radiological surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: drug has administered by a home care service for home treatment
Risk of bias
Bias Authors’ judgement Support for judgement
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Van Doormaal 2009 a (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned by a comput-
erized interactive voice response system”
Allocation concealment (selection bias) Low risk Quote: “Patients were randomly assigned by a comput-
erized interactive voice response system”
Blinding of patients? Low risk Quote: “double-blinded, placebo controlled study”
Comment: probably yes
Blinding of providers? Low risk Quote: “double-blinded, placebo controlled study”
Comment: probably yes
Blinding of data collectors? Low risk Quote: “double-blinded, placebo controlled study”
Comment: probably yes
Blinding of outcome adjudicators? Low risk Quote: “The study used central adjudication for all clin-
ical outcome events”
Comment: definitely yes
Blinding of data analysts? High risk Quote: “double-blinded, placebo controlled study”
Comment: probably not
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk Quote: “The analyses were calculated in the intention
to treat populations”
Comment: definitely yes
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in methods section are reported on in the
results section. All outcomes of interest, except for qual-
ity of life, reported
Free of other bias? Low risk Study not reported as stopped early for benefit
Van Doormaal 2009 b
Methods Randomized controlled study
Participants 240 cancer patients with acute symptomatic PE, with or with out associated DVT,
minimum age 18 years
Interventions Intervention: fondaparinx was given subcutaneously once daily in fixed dose(5 mg if
patients weighted less than 50 kg, or 7.5 mg if they weighted between 50 and 100 kg,
or 10 mg if they weighted more than 100kg) for 5-10 days
Control: UFH received an initial intravenous bolus of at least 5000 international units,
followed by at least 2500 international units per hour, administered as a continuous
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Van Doormaal 2009 b (Continued)
intravenous infusion. The infusion was adjusted tomaintain the activated partial throm-
boplastin time at 1.5 to 2.5 times control value
In all patients, VKA therapy was begun as soon as possible but not later than 72 hours
after commencing initial therapy and continued for at least 3 months
Outcomes Death, symptomatic recurrent VTE, bleeding
Notes Funding: Sanofi/ Organon
Follow up: 90 days
Radiologic surveillance: no scheduled radiological surveillance for VTE was conducted
Setting: 14.5 % of fondaparinux group received outpatient basis treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed at a central lo-
cation with the use of a computerized, interactive voice
response system that recorded information about the
patient before his or her treatment assignment”
Comment: definitely yes
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed at a central lo-
cation with the use of a computerized, interactive voice
response system that recorded information about the
patient before his or her treatment assignment”
Comment: definitely yes
Blinding of patients? High risk Quote: “was conducted on an open-label basis”
Comment: not blinded
Blinding of providers? High risk Quote: “was conducted on an open-label basis”
Comment: not blinded
Blinding of data collectors? High risk Quote: “was conducted on an open-label basis”
Comment: not blinded
Blinding of outcome adjudicators? Low risk Quote: “All suspected outcome events were reviewed
and classified by a central adjudication committee
whose members were unaware of the treatment assign-
ment”
Comment: definitely yes
Blinding of data analysts? High risk Quote: “was conducted on an open-label basis”
Comment: not blinded
Incomplete outcome data addressed? Low risk 100% follow-up rate
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Van Doormaal 2009 b (Continued)
Intention to treat analysis? Low risk Quote: “Efficacy analyses were based on data from all
the patients who had been randomly assigned to a study
group, whereas safety analyses were based on data from
all the patients who actually received treatment.”
Comment: yes for efficacy outcomes
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in methods section are reported on in the
results section. All outcomes of interest, except for qual-
ity of life, reported
Free of other bias? Low risk Study not reported as stopped early for benefit
Wells 2005
Methods Randomized controlled trial
Participants 113 cancer patients with upper or lower extremity, minimum age of 18 years
Interventions Intervention: tinzaparin 175 IU/kg subcutaneous once daily
Control: dalteparin SC 200 IU/kg once daily. Patients had to receive therapy on an
outpatient basis
Outcomes Deaths; symptomatic recurrent VTE; major bleeding; minor bleeding
Notes Funding: none
Follow up: 3 months
Radiological surveillance:no scheduled radiological surveillance for VTE was conducted
Setting: patients had receive therapy on outpatient basis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed in a computer
generated blocks, with the block size unknown to the
investigators”
Comment: definitely yes
Allocation concealment (selection bias) Low risk Quote: “Randomization assignments were concealed in
opaque envelopes. Envelopes were opened sequentially
and only after patient consent form was signed”
Comment: definitely yes
Blinding of patients? Low risk Based on personal communication with author
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Wells 2005 (Continued)
Blinding of providers? Low risk Quote: “All physicians and nurses who were involved in
the patient’s care were blinded except for the nurse who
provided the initial care to the patient”
Comment: definitely yes
Blinding of data collectors? Low risk Quote: “All physicians and nurses who were involved in
the patient’s care were blinded except for the nurse who
provided the initial care to the patient”
Comment: probably yes
Blinding of outcome adjudicators? Low risk Quote: “All physicians and nurses who were involved in
the patient’s care were blinded except for the nurse who
provided the initial care to the patient”
Comment: definitely yes
Blinding of data analysts? Low risk Based on personal communication with author
Incomplete outcome data addressed? Low risk 100% follow-up rate
Intention to treat analysis? Low risk Quote: “The primary analysis was intention to treat”
Comment: definitely yes
Free of selective reporting? Low risk Study not registered. No published protocol. All out-
comes listed in the methods section were reported on
Free of other bias? Low risk Study not stopped early for benefit
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Albada 1989 Data for cancer subgroup not available
Altundag 2005 Letter to editor
Anton 2001 Review
Bauer 2000 Editorial
Belcaro 1999 Data for cancer subgroup not available
Bick 2003 Review
Booth 1981 Case report
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Bratt 1985 No relevant clinical outcomes
Bratt 1990 Data for cancer subgroup not available
Brooks 1969 Case report
Buller 2004 Data for cancer subgroup not available
Dolovich 2004 Review
Douketis 2000 Cohort study
Eikelboom1998 Case series
Elly 1969 Case report
Fiessinger 1996 Data for cancer subgroup not available
Gould 1999 Review
Green 1992 Letter to editor
Haage 2002 Review
Handeland 1990 No cancer patients in the study
Harenberg 2000 Data for cancer subgroup not available
Harenberg 1990 Data for cancer subgroup not available
Hettiarachchi 1998 Review
Holm 1986 Data for cancer subgroup not available
Holmstrom 1999 Review
Hull 2000 Data for cancer subgroup not available
Hull 2006 Different long-term management: LMWH in intervention arm and vitamin K antagonists in control arm
Jahanzeb 2005 Review
Leizorovicz 1994 Review
Levine 2001 Review
Luomanmaki 1996 Data for cancer subgroup not available
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Martin-Carbonero2002 Cohort study
Menzoian 1983 Retrospective study
Naschitz 1994 Review
Prandoni 1988 No control group
Prandoni 1990 No cancer patients in the study
Prandoni 2005 Review
Riess 2003 Data for cancer subgroup not available
Sakuragi 2003 Retrospective study
Siragusa 2005 Not randomized
Turchetti 2003 Cohort study
Warkentin 1995 No relevant outcome
Wong 2003 Survey
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D A T A A N D A N A L Y S E S
Comparison 1. LMWH versus UFH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 3 months 11 801 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.52, 0.98]
2 Recurrent VTE 3 371 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.29, 2.08]
Comparison 2. Fondaparinux versus heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 477 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.88, 1.84]
2 Recurrent VTE 2 477 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.57, 1.60]
3 Major bleeding 2 477 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.39, 1.63]
4 Minor bleeding 2 477 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.87, 2.59]
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Analysis 1.1. Comparison 1 LMWH versus UFH, Outcome 1 Death at 3 months.
Review: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
Comparison: 1 LMWH versus UFH
Outcome: 1 Death at 3 months
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Columbus 1997 20/119 27/113 38.5 % 0.70 [ 0.42, 1.18 ]
Duroux 1991 0/6 2/12 1.2 % 0.37 [ 0.02, 6.71 ]
Galilei 2004 3/76 5/80 5.3 % 0.63 [ 0.16, 2.55 ]
Hull 1992 7/46 14/49 15.6 % 0.53 [ 0.24, 1.20 ]
Koopman 1996 3/34 3/36 4.4 % 1.06 [ 0.23, 4.89 ]
Levine 1996 11/46 14/57 21.8 % 0.97 [ 0.49, 1.94 ]
Lindmaker 1994 2/7 2/9 3.6 % 1.29 [ 0.24, 6.99 ]
Lopaciuk 1992 0/7 0/2 Not estimable
Prandoni 1992 1/15 6/18 2.6 % 0.20 [ 0.03, 1.48 ]
Simmoneau 1993 2/7 1/2 3.1 % 0.57 [ 0.09, 3.51 ]
Simmoneau 1997 2/26 4/34 3.9 % 0.65 [ 0.13, 3.30 ]
Total (95% CI) 389 412 100.0 % 0.71 [ 0.52, 0.98 ]
Total events: 51 (LMWH), 78 (UFH)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 9 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UFH
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Analysis 1.2. Comparison 1 LMWH versus UFH, Outcome 2 Recurrent VTE.
Review: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
Comparison: 1 LMWH versus UFH
Outcome: 2 Recurrent VTE
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Breddin 2001 1/33 7/41 18.9 % 0.18 [ 0.02, 1.37 ]
Galilei 2004 5/76 6/80 42.8 % 0.88 [ 0.28, 2.76 ]
Merli 2001 9/96 3/45 38.3 % 1.41 [ 0.40, 4.95 ]
Total (95% CI) 205 166 100.0 % 0.78 [ 0.29, 2.08 ]
Total events: 15 (LMWH), 16 (UFH)
Heterogeneity: Tau2 = 0.25; Chi2 = 2.96, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UFH
Analysis 2.1. Comparison 2 Fondaparinux versus heparin, Outcome 1 Death.
Review: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
Comparison: 2 Fondaparinux versus heparin
Outcome: 1 Death
Study or subgroup Fondaparinux Heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Doormaal 2009 a 23/126 17/111 44.7 % 1.19 [ 0.67, 2.11 ]
Van Doormaal 2009 b 28/112 24/128 55.3 % 1.33 [ 0.82, 2.16 ]
Total (95% CI) 238 239 100.0 % 1.27 [ 0.88, 1.84 ]
Total events: 51 (Fondaparinux), 41 (Heparin)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Fondaparinux Favours Heparin
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Analysis 2.2. Comparison 2 Fondaparinux versus heparin, Outcome 2 Recurrent VTE.
Review: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
Comparison: 2 Fondaparinux versus heparin
Outcome: 2 Recurrent VTE
Study or subgroup Fondaparinux Heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Doormaal 2009 a 16/126 6/111 23.7 % 2.35 [ 0.95, 5.79 ]
Van Doormaal 2009 b 10/112 22/128 76.3 % 0.52 [ 0.26, 1.05 ]
Total (95% CI) 238 239 100.0 % 0.95 [ 0.57, 1.60 ]
Total events: 26 (Fondaparinux), 28 (Heparin)
Heterogeneity: Chi2 = 6.70, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Fondaparinux Favours Heparin
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Analysis 2.3. Comparison 2 Fondaparinux versus heparin, Outcome 3 Major bleeding.
Review: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
Comparison: 2 Fondaparinux versus heparin
Outcome: 3 Major bleeding
Study or subgroup Fondaparinux Heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Doormaal 2009 a 9/126 8/111 53.3 % 0.99 [ 0.40, 2.48 ]
Van Doormaal 2009 b 4/112 8/128 46.7 % 0.57 [ 0.18, 1.85 ]
Total (95% CI) 238 239 100.0 % 0.79 [ 0.39, 1.63 ]
Total events: 13 (Fondaparinux), 16 (Heparin)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 2.4. Comparison 2 Fondaparinux versus heparin, Outcome 4 Minor bleeding.
Review: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
Comparison: 2 Fondaparinux versus heparin
Outcome: 4 Minor bleeding
Study or subgroup Fondaparinux Heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Doormaal 2009 a 15/126 12/111 66.1 % 1.10 [ 0.54, 2.25 ]
Van Doormaal 2009 b 14/112 7/128 33.9 % 2.29 [ 0.96, 5.46 ]
Total (95% CI) 238 239 100.0 % 1.50 [ 0.87, 2.59 ]
Total events: 29 (Fondaparinux), 19 (Heparin)
Heterogeneity: Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Fondaparinux Favours Heparin
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A D D I T I O N A L T A B L E S
Table 1. Glossary
Term Definition
A priori made before or without examination; not supported by factual study
Adjuvant therapy assisting in the amelioration, or cure of disease
Anticoagulation the process of hindering the clotting of blood especially by treatment with an anticoagulant
Antithrombotic used against or tending to prevent thrombosis (clotting)
Coagulation clotting
Deep vein thrombosis (DVT): a condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that
may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially
life threatening if dislodgment of the thrombus results in pulmonary embolism
Fondaparinux an anticoagulant medication
Haemostatic system the system that shortens the clotting time of blood and stops bleeding
Heparin an enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by
preventing the formation of fibrin. Two forms of heparin that are used as anticoagulant medications
are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH)
Heterogeneity the quality or state of being heterogeneous, i.e. incongruous. This is a statistical technique to check
whether study results are consistent
Hypercoagulable state a state of excessive affinity to clotting
Impedance plethysmography a technique that measures the change in blood volume (venous blood volume as well as the pulsation
of the arteries) for a specific body segment
Kappa statistic a measure of degree of nonrandom agreement between observers and/or measurements of a specific
categorical variable
Metastasis the spread of a cancer cells from the initial or primary site of disease to another part of the body
Parenteral nutrition the practice of feeding a patient intravenously, circumventing the gut
Pulmonary embolism (PE) embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most
often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing,
chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death
Thrombocytopenia persistent decrease in the number of blood platelets that is often associated with hemorrhagic
conditions
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Table 1. Glossary (Continued)
Thrombosis the formation or presence of a blood clot within a blood vessel
Vitamin K antagonists anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist
Warfarin an anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation
Ximelagatran an anticoagulant medication
A P P E N D I C E S
Appendix 1. Search strategies for the electronic databases
Database Strategy
MEDLINE #1 Heparin/
#2 Heparin.tw
#3 Heparin, Low-Molecular-Weight/
#4 (LMWH OR low molecular weight heparin OR nadroparin OR
fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin
OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logi-
parin OR innohep OR certoparin OR sandoparin OR reviparin OR
clivarin OR danaproid OR orgaran).tw
#5 1 OR 2 OR 3 OR 4
#6 Coumarins/
#7 Warfarin/
#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon
OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K an-
tagonist OR VKA).tw
#9 6 OR 7 OR 8
#10 (fondaparinux OR Arixtra).tw
#11 (ximelagatran OR Exanta).tw
#12 (Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban).
tw.
#13 5 OR 9 OR 10 OR 11 OR 12
#14 Neoplasms/
#15 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor).tw
#16 14 OR 15
#17 clinical trial.pt. OR random:.tw. OR tu.xs.
#18 animals/ NOT human/
#19 17 NOT 18
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#20 13 AND 16 AND 19
EMBASE #1 Heparin/
#2 heparin.tw
#3 Low Molecular Weight Heparin/
#4 (LMWH OR low molecular weight heparin OR nadroparin OR
fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin
OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logi-
parin OR innohep OR certoparin OR sandoparin OR reviparin OR
clivarin OR danaproid OR orgaran).tw
#5 1 OR 2 OR 3 OR 4
#6 Coumarin derivative/
#7 Warfarin/
#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon
OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K an-
tagonist OR VKA).tw
#9 6 OR 7 OR 8
#10 fondaparinux/
#11 (fondaparinux OR Arixtra).tw
#12 ximelagatran/
#13 (ximelagatran OR Exanta).tw
#14 (Pradaxa ORDabigatran OR rivaroxaban OR Xarelto OR apix-
aban).tw.
#15 5 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14
#16 Neoplasm/
#17 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor).tw
#18 16 OR 17
#19 Random:.tw. OR clinical trial:.mp. OR exp health care quality
#20 animals/ NOT human/
#21 19 NOT 20
#22 15 AND 18 AND 21
ISI (International Scientific Information) the Web of Science #1 heparin OR low molecular weight heparin OR LMWHOR low-
molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxa-
parin OR clexane OR lovenox OR dalteparin OR fragmin OR arde-
parin OR normiflo OR tinzaparin OR logiparin OR innohep OR
certoparin OR sandoparin OR reviparin OR clivarin OR danaproid
OR orgaran
#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR
phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR
vitamin K antagonist OR VKA
#3 fondaparinux OR Arixtra
#4 ximelagatran OR Exanta
# 5 Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apix-
aban
#6 1 OR 2 OR 3 OR 4 OR 5
#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR ade-
nocarcinoma OR tumour OR tumor
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#8 random$ OR placebo$ OR versus OR vs OR double blind OR
double-blind OR compar$ OR controlled
#9 6 AND 7 AND 8
CENTRAL (The Cochrane Library, latest issue) #1 heparin OR low molecular weight heparin OR LMWHOR low-
molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxa-
parin OR clexane OR lovenox OR dalteparin OR fragmin OR arde-
parin OR normiflo OR tinzaparin OR logiparin OR innohep OR
certoparin OR sandoparin OR reviparin OR clivarin OR danaproid
OR orgaran
#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR
phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR
vitamin K antagonist OR VKA
#3 fondaparinux OR Arixtra
#4 ximelagatran OR Exanta
#5 Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban
#6 1 OR 2 OR 3 OR 4 OR 5
#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR ade-
nocarcinoma OR tumour OR tumor
#8 6 AND 7
F E E D B A C K
Cochrane Editorial Unit’s report on feedback on anticoagulants reviews, 15 February 2011
Summary
Feedback received on this review, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit website
at http://www.editorial-unit.cochrane.org/anticoagulants-feedback.
Reply
N/A
Contributors
N/A
58Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Date Event Description
28 November 2012 Amended Author contact details updated
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 1, 2008
Date Event Description
13 January 2011 New citation required but conclusions have not
changed
Updated search (February 2010)
13 January 2011 New search has been performed Text revisions incorporated. New author added.
5 November 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
EAA: protocol development, search for trials, screening, data extraction, data analysis, manuscript drafting, review coordination. SR:
screening, data extraction. MB: screening, data extraction.
FS: screening, data extraction.
IT: screening, data extraction.
PM: data analysis, methodological advice.
HJS: protocol development, search for trials, data extraction, data analysis, methodological advice.
D E C L A R A T I O N S O F I N T E R E S T
None
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